Table 5.
Overview of ERBB2 amplification.
| Study | Study design | N | ERBB2 Amplification | Assay |
|---|---|---|---|---|
| LA/mUC | ||||
| Jacob 2021 | Observational | 49 | 2.0% | N/A |
| Cabel 2018 | Pooled analysis of clinical trials | 44 | 2.3% | N/A |
| Pobel 2021 | Pooled analysis of clinical trials | 182 | 2.7% | N/A |
| Ross 2014 | Observational | 35 | 2.9% | N/A |
| Alhalabi 2021 | Clinical trial, phase I | 41 | 4.9% | N/A |
| Vandekerkhove 2021 | Observational | 104 | 6.7% | N/A |
| Almassi 2019 | Observational | 131 | 6.9% | N/A |
| Madison 2020 | Observational | 3,753 | 7.4% | N/A |
| Agarwal 2018 | Observational | 369 | 8.1% | N/A |
| Ross 2016 | Observational | 295 | 8.5% | N/A |
| Sarid 2019 | Observational | 60 | 10.0% | N/A |
| Millis 2015 | Observational | 284 | 11.6% | N/A |
| Villamar 2019 | Observational | 214 | 12.8% | N/A |
| Choudhury 2016 | Clinical trial, phase II | 23 | 13.0% | ThermoFisher Scientific Ion AmpliSeq Library Kit and Comprehensive Cancer Panel |
| Vandekerkhove 2017 | Observational | 26 | 19.2% | N/A |
| Fina 2016 | Observational | 31 | 22.6% | N/A |
| Weighted average: 7.8% | ||||
| Earlier stage UC | ||||
| Almassi 2019 | Observational | 491 | 9.0% | N/A |
| Weighted average: 9.0% | ||||
ERBB2, Erb-B2 receptor tyrosine kinase 2; N/A, not available.